Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18855724rdf:typepubmed:Citationlld:pubmed
pubmed-article:18855724lifeskim:mentionsumls-concept:C0013227lld:lifeskim
pubmed-article:18855724lifeskim:mentionsumls-concept:C0250501lld:lifeskim
pubmed-article:18855724lifeskim:mentionsumls-concept:C1518581lld:lifeskim
pubmed-article:18855724lifeskim:mentionsumls-concept:C1521840lld:lifeskim
pubmed-article:18855724pubmed:issue11lld:pubmed
pubmed-article:18855724pubmed:dateCreated2008-10-15lld:pubmed
pubmed-article:18855724pubmed:abstractTextThere has been considerable in vivo evidence that chemokine receptor CXCR4 and its endogenous ligand CXCL12 modulate some important physiological and pathophysiological processes, including cancer metastasis, angiogenesis, invasion, growth and progression. In this review we elucidate key aspects of CXCL12-CXCR4 signaling system with emphasis on peptide-based and small-molecule CXCR4 inhibitors.lld:pubmed
pubmed-article:18855724pubmed:languageenglld:pubmed
pubmed-article:18855724pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18855724pubmed:citationSubsetIMlld:pubmed
pubmed-article:18855724pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18855724pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18855724pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18855724pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18855724pubmed:statusMEDLINElld:pubmed
pubmed-article:18855724pubmed:monthOctlld:pubmed
pubmed-article:18855724pubmed:issn1389-5575lld:pubmed
pubmed-article:18855724pubmed:authorpubmed-author:IvachtchenkoA...lld:pubmed
pubmed-article:18855724pubmed:authorpubmed-author:BalakinKonsta...lld:pubmed
pubmed-article:18855724pubmed:authorpubmed-author:IvanenkovYan...lld:pubmed
pubmed-article:18855724pubmed:authorpubmed-author:LavrovskyYanYlld:pubmed
pubmed-article:18855724pubmed:authorpubmed-author:MedvedevaDary...lld:pubmed
pubmed-article:18855724pubmed:issnTypePrintlld:pubmed
pubmed-article:18855724pubmed:volume8lld:pubmed
pubmed-article:18855724pubmed:ownerNLMlld:pubmed
pubmed-article:18855724pubmed:authorsCompleteYlld:pubmed
pubmed-article:18855724pubmed:pagination1075-87lld:pubmed
pubmed-article:18855724pubmed:meshHeadingpubmed-meshheading:18855724...lld:pubmed
pubmed-article:18855724pubmed:meshHeadingpubmed-meshheading:18855724...lld:pubmed
pubmed-article:18855724pubmed:meshHeadingpubmed-meshheading:18855724...lld:pubmed
pubmed-article:18855724pubmed:meshHeadingpubmed-meshheading:18855724...lld:pubmed
pubmed-article:18855724pubmed:meshHeadingpubmed-meshheading:18855724...lld:pubmed
pubmed-article:18855724pubmed:meshHeadingpubmed-meshheading:18855724...lld:pubmed
pubmed-article:18855724pubmed:meshHeadingpubmed-meshheading:18855724...lld:pubmed
pubmed-article:18855724pubmed:meshHeadingpubmed-meshheading:18855724...lld:pubmed
pubmed-article:18855724pubmed:year2008lld:pubmed
pubmed-article:18855724pubmed:articleTitleCXCR4 receptor as a promising target for oncolytic drugs.lld:pubmed
pubmed-article:18855724pubmed:affiliationSmall Molecule Drug Discovery, ChemDiv, Inc., San Diego, California 92121, USA.lld:pubmed
pubmed-article:18855724pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18855724pubmed:publicationTypeReviewlld:pubmed